Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | NUVB |
---|---|---|
09:33 ET | 132900 | 2.94 |
09:35 ET | 20267 | 2.93 |
09:37 ET | 5093 | 2.9 |
09:39 ET | 16071 | 2.905 |
09:42 ET | 15971 | 2.9198 |
09:44 ET | 7789 | 2.9 |
09:46 ET | 5244 | 2.8892 |
09:48 ET | 300 | 2.89 |
09:50 ET | 15588 | 2.89 |
09:51 ET | 13990 | 2.9 |
09:53 ET | 6526 | 2.8984 |
09:55 ET | 6207 | 2.8798 |
09:57 ET | 3517 | 2.885 |
10:00 ET | 2247 | 2.86 |
10:02 ET | 454 | 2.86 |
10:04 ET | 5601 | 2.87 |
10:06 ET | 3100 | 2.865 |
10:08 ET | 9993 | 2.865 |
10:09 ET | 3470 | 2.855 |
10:11 ET | 4500 | 2.8611 |
10:13 ET | 7974 | 2.8407 |
10:15 ET | 4173 | 2.87 |
10:18 ET | 3988 | 2.875 |
10:20 ET | 3353 | 2.895 |
10:22 ET | 17443 | 2.9 |
10:24 ET | 20624 | 2.885 |
10:26 ET | 2901 | 2.88 |
10:27 ET | 44481 | 2.85 |
10:29 ET | 15842 | 2.865 |
10:31 ET | 13929 | 2.86 |
10:33 ET | 69715 | 2.885 |
10:36 ET | 78101 | 2.88 |
10:38 ET | 60420 | 2.925 |
10:40 ET | 19454 | 2.895 |
10:42 ET | 155542 | 2.915 |
10:44 ET | 83684 | 2.915 |
10:45 ET | 20087 | 2.9389 |
10:47 ET | 7793 | 2.945 |
10:49 ET | 10940 | 2.9499 |
10:51 ET | 1650 | 2.95 |
10:54 ET | 5225 | 2.955 |
10:56 ET | 900 | 2.955 |
10:58 ET | 1108 | 2.96 |
11:00 ET | 13025 | 2.95 |
11:02 ET | 2750 | 2.955 |
11:03 ET | 100 | 2.9509 |
11:05 ET | 21101 | 3 |
11:07 ET | 16898 | 3 |
11:09 ET | 5724 | 3.01 |
11:12 ET | 506279 | 3.04 |
11:14 ET | 54279 | 3.06 |
11:16 ET | 19383 | 3.065 |
11:18 ET | 18415 | 3.055 |
11:20 ET | 26281 | 3.055 |
11:21 ET | 3232 | 3.07 |
11:23 ET | 5900 | 3.075 |
11:25 ET | 37952 | 3.0452 |
11:27 ET | 11535 | 3.05 |
11:30 ET | 20003 | 3.01 |
11:32 ET | 5643 | 3.015 |
11:34 ET | 12663 | 3 |
11:36 ET | 2579 | 3.005 |
11:38 ET | 15757 | 3.023 |
11:39 ET | 13638 | 3.029 |
11:41 ET | 1754 | 3.025 |
11:43 ET | 1638 | 3.03 |
11:45 ET | 18871 | 3.025 |
11:48 ET | 3703 | 3.015 |
11:50 ET | 10006 | 3.015 |
11:52 ET | 4108 | 3.005 |
11:54 ET | 7099 | 3.015 |
11:56 ET | 300 | 3.015 |
11:57 ET | 5558 | 3.005 |
11:59 ET | 60027 | 3.01 |
12:03 ET | 331 | 3.0195 |
12:06 ET | 200 | 3.02 |
12:08 ET | 14802 | 3.03 |
12:10 ET | 5500 | 3.0273 |
12:14 ET | 10667 | 3.05 |
12:15 ET | 15070 | 3.04 |
12:17 ET | 32202 | 3.025 |
12:19 ET | 694 | 3.025 |
12:21 ET | 523 | 3.025 |
12:24 ET | 3872 | 3.03 |
12:26 ET | 67399 | 3.0082 |
12:28 ET | 1000 | 3 |
12:30 ET | 401 | 3.005 |
12:32 ET | 26996 | 3.01 |
12:33 ET | 4520 | 3.005 |
12:35 ET | 9823 | 3.015 |
12:37 ET | 331 | 3.02 |
12:39 ET | 29140 | 3.005 |
12:42 ET | 800 | 3 |
12:44 ET | 78250 | 2.995 |
12:46 ET | 64608 | 2.99 |
12:48 ET | 100 | 2.99 |
12:50 ET | 200 | 2.99 |
12:51 ET | 200 | 2.99 |
12:53 ET | 13626 | 3.01 |
12:55 ET | 13559 | 3.005 |
12:57 ET | 105 | 2.995 |
01:00 ET | 16688 | 2.985 |
01:02 ET | 256769 | 2.99 |
01:04 ET | 111268 | 2.97 |
01:06 ET | 18741 | 2.94 |
01:08 ET | 3100 | 2.935 |
01:09 ET | 26588 | 2.96 |
01:11 ET | 3300 | 2.97 |
01:13 ET | 19650 | 2.96 |
01:15 ET | 37786 | 2.9779 |
01:18 ET | 1578 | 2.98 |
01:20 ET | 1122 | 2.975 |
01:22 ET | 915 | 2.98 |
01:24 ET | 15763 | 2.975 |
01:26 ET | 10297 | 2.99 |
01:27 ET | 11844 | 2.9952 |
01:29 ET | 1100 | 2.9941 |
01:31 ET | 24412 | 2.995 |
01:33 ET | 16789 | 3.005 |
01:36 ET | 4100 | 3 |
01:38 ET | 19644 | 3.02 |
01:40 ET | 2671 | 3.03 |
01:42 ET | 3947 | 3.0257 |
01:44 ET | 937 | 3.03 |
01:45 ET | 3122 | 3.025 |
01:47 ET | 802 | 3.025 |
01:49 ET | 3086 | 3.025 |
01:51 ET | 12914 | 3.0189 |
01:54 ET | 922 | 3.015 |
01:56 ET | 2995 | 3.015 |
01:58 ET | 25120 | 3.015 |
02:00 ET | 2300 | 3.015 |
02:02 ET | 100 | 3.015 |
02:03 ET | 12892 | 3.01 |
02:05 ET | 2704 | 3.01 |
02:07 ET | 11196 | 3.015 |
02:09 ET | 400 | 3.015 |
02:12 ET | 1839 | 3.0188 |
02:14 ET | 12182 | 3.005 |
02:16 ET | 954 | 3 |
02:18 ET | 8570 | 3.01 |
02:20 ET | 1207 | 3.005 |
02:21 ET | 7472 | 3.005 |
02:23 ET | 1500 | 3 |
02:25 ET | 40041 | 3.0099 |
02:27 ET | 776 | 3 |
02:30 ET | 1612 | 3 |
02:32 ET | 5430 | 3 |
02:34 ET | 24630 | 3.015 |
02:36 ET | 6918 | 3.015 |
02:38 ET | 14564 | 3 |
02:39 ET | 1050 | 3 |
02:41 ET | 1852 | 3.01 |
02:43 ET | 8673 | 3.005 |
02:45 ET | 2201 | 3.01 |
02:48 ET | 4186 | 3.01 |
02:50 ET | 23043 | 3.015 |
02:52 ET | 3087 | 3.02 |
02:54 ET | 1300 | 3.02 |
02:56 ET | 8146 | 3.013 |
02:57 ET | 20523 | 3.02 |
02:59 ET | 4284 | 3.02 |
03:01 ET | 5780 | 3.015 |
03:03 ET | 3611 | 3.02 |
03:06 ET | 7739 | 3.01 |
03:08 ET | 7244 | 3.02 |
03:10 ET | 3362 | 3.02 |
03:12 ET | 6775 | 3.02 |
03:14 ET | 3100 | 3.02 |
03:15 ET | 6796 | 3.015 |
03:17 ET | 6913 | 3.01 |
03:19 ET | 9417 | 3.01 |
03:21 ET | 3300 | 3.02 |
03:24 ET | 33235 | 3.04 |
03:26 ET | 11674 | 3.045 |
03:28 ET | 29657 | 3.04 |
03:30 ET | 24967 | 3.025 |
03:32 ET | 8251 | 3.01 |
03:33 ET | 5342 | 3.015 |
03:35 ET | 12940 | 3.025 |
03:37 ET | 11549 | 3.015 |
03:39 ET | 9725 | 3.015 |
03:42 ET | 20184 | 3.01 |
03:44 ET | 19399 | 3.005 |
03:46 ET | 2653 | 3.01 |
03:48 ET | 5735 | 3.01 |
03:50 ET | 30640 | 3.015 |
03:51 ET | 51722 | 3.005 |
03:53 ET | 10150 | 3 |
03:55 ET | 25402 | 3 |
03:57 ET | 38896 | 3 |
04:00 ET | 270635 | 3.01 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Nuvation Bio Inc | 1.0B | -1.4x | --- |
CARGO Therapeutics Inc | 1.0B | -6.3x | --- |
Cullinan Therapeutics Inc | 1.0B | -6.0x | --- |
Rapport Therapeutics Inc | 983.9M | -15.2x | --- |
LENZ Therapeutics Inc | 983.2M | -3.8x | --- |
89Bio Inc | 1.1B | -3.5x | --- |
Nuvation Bio Inc. is a biopharmaceutical company. The Company is engaged in tackling the unmet needs in oncology by developing differentiated and therapeutic candidates. The Company is advancing multiple clinical-stage candidates, including a ROS1 inhibitor, a mutant isocitrate dehydrogenase 1 (mIDH1) inhibitor, a bromodomain and extra-terminal (BET) inhibitor, and a drug-drug conjugate (DDC). Its portfolio of development candidates includes taletrectinib (ROS1), safusidenib (mIDH1), NUV-868 (BET), and NUV-1511 (DDC). Taletrectinib is an oral, potent, CNS-active, selective, ROS1 inhibitor specifically designed for the potential treatment of ROS1-positive non-small cell lung cancer (NSCLC). Safusidenib is an oral, potent, targeted inhibitor of mIDH1 being evaluated in a global Phase II trial in patients with low-grade IDH1-mutant glioma. NUV-868 is a BD2-selective oral small molecule BET inhibitor, that inhibits BRD4. It is conducting Phase I/II study of NUV-1511.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $1.0B |
---|---|
Revenue (TTM) | $2.2M |
Shares Outstanding | 336.6M |
Nuvation Bio Inc does not pay a dividend. | |
Beta | 1.47 |
EPS | $-2.17 |
Book Value | $2.76 |
P/E Ratio | -1.4x |
Price/Sales (TTM) | 468.6 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -25,879.56% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.